"Molecular Switches" on MGluR Allosteric Ligands That Modulate Modes of Pharmacology

Overview

Journal Biochemistry

Specialty Biochemistry

Date 2011 Feb 24

PMID 21341760

Citations 80

Authors

Michael R Wood

Corey R Hopkins

John T Brogan

P Jeffrey Conn

Craig W Lindsley

Affiliations

Soon will be listed here.

Abstract

G-protein-coupled receptors (GPCRs) represent the largest class of drug targets, accounting for more than 40% of marketed drugs; however, discovery efforts for many GPCRs have failed to provide viable drug candidates. Historically, drug discovery efforts have focused on developing ligands that act at the orthosteric site of the endogenous agonist. Recently, efforts have focused on functional assay paradigms and the discovery of ligands that act at allosteric sites to modulate receptor function in either a positive, negative, or neutral manner. Allosteric modulators have numerous advantages over orthosteric ligands, including high subtype selectivity; the ability to mimic physiological conditions; the lack of densensitization, downregulation, and internalization; and reduced side effects. Despite these virtues, challenging issues have now arisen for allosteric modulators of metabotropic glutamate receptors (mGluRs): shallow SAR, ligand-directed trafficking, and the identification of subtle "molecular switches" that modulate the modes of pharmacology. Here, we will discuss the impact of modest structural changes to multiple mGluR allosteric ligands scaffolds that unexpectedly modulate pharmacology and raise concerns over metabolism and the pharmacology of metabolites.

Citing Articles

mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders.

Domin H, Burnat G Pharmacol Rep. 2024; 76(6):1219-1241.

PMID: 39348087 PMC: 11582148. DOI: 10.1007/s43440-024-00657-7.

The novel peptide LCGM-10 attenuates metabotropic glutamate receptor 5 activity and demonstrates behavioral effects in animal models.

Malyshev A, Pavshintcev V, Mitkin N, Sukhanova I, Gedzun V, Zlobin A Front Behav Neurosci. 2024; 18:1333258.

PMID: 38385004 PMC: 10879279. DOI: 10.3389/fnbeh.2024.1333258.

Metabotropic Glutamate Receptor Subtype 5 Positron-Emission-Tomography Radioligands as a Tool for Central Nervous System Drug Development: Between Progress and Setbacks.

Dupont A, Arlicot N, Vercouillie J, Serriere S, Maia S, Bonnet-Brilhault F Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631042 PMC: 10458693. DOI: 10.3390/ph16081127.

Discovery of "Molecular Switches" within a Series of mGlu Allosteric Ligands Driven by a "Magic Methyl" Effect Affording Both PAMs and NAMs with Activity, Derived from an M PAM Chemotype.

Barbaro L, Rodriguez A, Blevins A, Dickerson J, Billard N, Boutaud O ACS Bio Med Chem Au. 2023; 1(1):21-30.

PMID: 37101980 PMC: 10114714. DOI: 10.1021/acsbiomedchemau.1c00024.

PET imaging studies to investigate functional expression of mGluR2 using [C]mG2P001.

Yuan G, Dhaynaut M, Guehl N, Neelamegam R, Moon S, Qu X J Cereb Blood Flow Metab. 2022; 43(2):296-308.

PMID: 36172629 PMC: 9903221. DOI: 10.1177/0271678X221130387.

References

OBrien J, Lemaire W, Chen T, Chang R, Jacobson M, Ha S . A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol. 2003; 64(3):731-40. DOI: 10.1124/mol.64.3.731. View

Conn P, Pin J . Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997; 37:205-37. DOI: 10.1146/annurev.pharmtox.37.1.205. View

Swanson C, Bures M, Johnson M, Linden A, Monn J, Schoepp D . Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005; 4(2):131-44. DOI: 10.1038/nrd1630. View

Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G . ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive.... J Pharmacol Exp Ther. 2008; 327(3):827-39. DOI: 10.1124/jpet.108.136580. View

Lindsley C, Niswender C, Engers D, Hopkins C . Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Curr Top Med Chem. 2009; 9(10):949-63. View

Bridges T, Lindsley C . G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol. 2008; 3(9):530-41. DOI: 10.1021/cb800116f. View

Lorenzen T . Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients. HIV AIDS (Auckl). 2011; 2:151-6. PMC: 3218686. DOI: 10.2147/HIV.S4787. View

Rodriguez A, Grier M, Jones C, Herman E, Kane A, Smith R . Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010; 78(6):1105-23. PMC: 2993468. DOI: 10.1124/mol.110.067207. View

Schoepp D, Jane D, Monn J . Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 1999; 38(10):1431-76. DOI: 10.1016/s0028-3908(99)00092-1. View

10.

Knoflach F, Mutel V, Jolidon S, Kew J, Malherbe P, Vieira E . Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001; 98(23):13402-7. PMC: 60883. DOI: 10.1073/pnas.231358298. View

11.

Williams R, Zhou Y, Niswender C, Luo Q, Conn P, Lindsley C . Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. ACS Chem Neurosci. 2010; 1(6):411-419. PMC: 2889702. DOI: 10.1021/cn9000318. View

12.

Christopoulos A . Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov. 2002; 1(3):198-210. DOI: 10.1038/nrd746. View

13.

Zhou Y, Rodriguez A, Williams R, Weaver C, Conn P, Lindsley C . Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009; 19(23):6502-6. PMC: 3177597. DOI: 10.1016/j.bmcl.2009.10.059. View

14.

Jensen A, Spalding T . Allosteric modulation of G-protein coupled receptors. Eur J Pharm Sci. 2004; 21(4):407-20. DOI: 10.1016/j.ejps.2003.11.007. View

15.

Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor P, Vranesic I . CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol. 1999; 55(3):453-61. View

16.

Rodriguez A, Williams R, Zhou Y, Lindsley S, Le U, Grier M . Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. Bioorg Med Chem Lett. 2009; 19(12):3209-13. PMC: 3177605. DOI: 10.1016/j.bmcl.2009.04.110. View

17.

Digby G, Conn P, Lindsley C . Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Curr Opin Drug Discov Devel. 2010; 13(5):587-94. PMC: 3821179. View

18.

Engers D, Rodriguez A, Williams R, Hammond A, Venable D, Oluwatola O . Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273. ChemMedChem. 2009; 4(4):505-11. PMC: 2865690. DOI: 10.1002/cmdc.200800357. View

19.

Harrington P, Fotsch C . Calcium sensing receptor activators: calcimimetics. Curr Med Chem. 2008; 14(28):3027-34. DOI: 10.2174/092986707782794096. View

20.

Kinney G, OBrien J, Lemaire W, Burno M, Bickel D, Clements M . A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther. 2004; 313(1):199-206. DOI: 10.1124/jpet.104.079244. View